Gli anticorpi contro l’antigene core di HBV (anti-HBc) sono presenti nel 14-44% dei pazienti con infezione da HIV. Rimane una problematica dibattuta se la vaccinazione anti HBV debba essere consigliata ai pazienti HIV positivi con isolata positività per anti-HBc (IAHBC). Ci siamo proposti di indagare...
Background: Some studies have analyzed the relationship between circulating cytokines and cardiovascular risk and some authors pose a threshold at 3.2 pg/mL for a significant increase. Effects of DAAs on circulating cytokines in HCV-infected patients are still unknown. Methods: We retrospectively evaluated HCV- and HCV-HIV-infected patients...
Background. This study evaluated the long-term efficacy and safety of an 18-month lamivudine prophylaxis in 68 HBsAg-negative/anti-HBc-positive patients with onco-hematological disease. Patients ad Methods. All 68 consecutive HBsAg-negative/anti-HBc-positive patients with an onco-hematological disease and naïve for chemotherapy observed from April 2008 to December 2012 at two...
This work examined the trend of the estimated glomerular filtration rate (eGFR) of patients included in the SIMIT compassionate use program of ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV). HIV/HCV genotype 1 co-infected patients with creatinine levels available at baseline (BL), at the end of treatment (EoT) and...
Background. We evaluated adherence and efficacy of DAA-regimens in a drug-users cohort. Methods. Adherence of drug-users HCV patients was calculated as percentage of visits attended among those scheduled (monthly during treatment and follow-up). Regularity of medication uptake was investigated by questionnaires. Results. 78 drug-users, who received at...
BACKGROUND Despite the high rates of HIV control achieved by current antiretroviral therapy, HIV/HCV co-infection still has an unfavorable influence on the natural history of HCV, resulting in an increased rate of progression to cirrhosis, HCC and end stage liver disease. Although direct acting antivirals have...
Background. hsa-miR-125a-5p, a microRNA expressed in human liver, was shown to inhibit the expression of HBsAg in vitro. Aims. To correlate the hepatic expression pattern of hsa-miR-125a-5p with the concentrations of HBV-DNA in liver tissue and the progression of fibrosis in 74 consecutive patients with...
AIM. To assess and compare the diagnostic reliability for the staging of liver fibrosis of two indirect biomarkers, APRI and FIB-4, using transient elastography (TE) as reference standard, among HIV/HCV and HCV monoinfected patients. MATERIALS&METHODS. This is an observational, retrospective study. All patients underwent blood tests...
Increased levels (lvs) of chemokine interferon-γ-inducible protein-10 (CXCL10), soluble (s) CD163 and sCD14 have been reported in HCV infection. The aim of this study was to compare biomarkers lvs in HCV-infected patients (pts) undergoing direct acting antiviral (DAA) regimens with or without interferon (IFN). sCD163, sCD14...
BACKGROUND/AIMS: To evaluate the efficacy of Direct Antiviral Agents (DAA)-based regimen in HBsAg/anti-HCV/HCV-RNA-positive patients (pts) in terms of sustained virolgical response for HCV and of reactivation of HBV infection. METHODS: In a multicentric, prospective study we enrolled 29HBsAg/anti-HCV-positive pts treated with DAA . At the time...